MAINZ BIOMED B V's ticker is and the CUSIP is N5436L101. A total of 4 filers reported holding MAINZ BIOMED B V in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $286 | -93.6% | 98 | -89.5% | 0.00% | – |
Q2 2023 | $4,450 | -67.8% | 931 | -57.8% | 0.00% | – |
Q1 2023 | $13,841 | -12.2% | 2,204 | -0.7% | 0.00% | – |
Q4 2022 | $15,762 | +21.2% | 2,220 | +62.8% | 0.00% | – |
Q2 2022 | $13,000 | -38.1% | 1,364 | -5.6% | 0.00% | – |
Q1 2022 | $21,000 | -76.7% | 1,445 | -83.4% | 0.00% | – |
Q4 2021 | $90,000 | – | 8,710 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Greenwich Investment Management, Inc. | 13,909 | $41,000 | 0.03% |
UBS Group AG | 98 | $286 | 0.00% |
NewEdge Advisors, LLC | 1,000 | $2,920 | 0.00% |
WELLS FARGO & COMPANY/MN | 200 | $584 | 0.00% |
CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
CITIGROUP INC | 673 | $1,965 | 0.00% |
MORGAN STANLEY | 200 | $584 | 0.00% |
Steward Partners Investment Advisory, LLC | 1,500 | $4,380 | 0.00% |
JPMORGAN CHASE & CO | 2,569 | $7,501 | 0.00% |